These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 10377815

  • 1. [Increased vascular endothelial growth factor (VEGF) is causative in Crow-Fukase syndrome].
    Arimura K.
    Rinsho Shinkeigaku; 1999 Jan; 39(1):84-5. PubMed ID: 10377815
    [Abstract] [Full Text] [Related]

  • 2. [Vascular endothelial growth factor and Crow-Fukase syndrome].
    Arimura K, Osame M, Hashiguchi T.
    Rinsho Shinkeigaku; 2001 Dec; 41(12):1144-6. PubMed ID: 12235821
    [Abstract] [Full Text] [Related]

  • 3. [Crow-Fukase syndrome and VEGF].
    Arimura K, Hashiguchi T, Watanabe O.
    Brain Nerve; 2008 Jun; 60(6):611-9. PubMed ID: 18567356
    [Abstract] [Full Text] [Related]

  • 4. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome.
    Watanabe O, Maruyama I, Arimura K, Kitajima I, Arimura H, Hanatani M, Matsuo K, Arisato T, Osame M.
    Muscle Nerve; 1998 Nov; 21(11):1390-7. PubMed ID: 9771661
    [Abstract] [Full Text] [Related]

  • 5. [A case of polyneuropathy associated with increased levels of vascular endotherial growth factor (VEGF) insera].
    Shibuya S, Aihara N, Tsukamoto T, Itoyama Y.
    Rinsho Shinkeigaku; 2001 Oct; 41(10):665-7. PubMed ID: 11993185
    [Abstract] [Full Text] [Related]

  • 6. [Crow-Fukase (POEMS) syndrome].
    Hashiguchi T, Arimura K, Osame M.
    Ryoikibetsu Shokogun Shirizu; 2000 Oct; (32):595-8. PubMed ID: 11212815
    [No Abstract] [Full Text] [Related]

  • 7. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
    Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E.
    Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
    [Abstract] [Full Text] [Related]

  • 8. Effects of pericytes and various cytokines on integrity of endothelial monolayer originated from blood-nerve barrier: an in vitro study.
    Iwasaki T, Kanda T, Mizusawa H.
    J Med Dent Sci; 1999 Mar; 46(1):31-40. PubMed ID: 12160211
    [Abstract] [Full Text] [Related]

  • 9. [Two cases of POEMS syndrome with increased vascular endothelial growth factor (VEGF)].
    Arimura H, Watanabe O, Arimura K, Maruyama I, Hokezu Y.
    Rinsho Shinkeigaku; 1997 Sep; 37(9):817-23. PubMed ID: 9430997
    [Abstract] [Full Text] [Related]

  • 10. [Paraneoplastic Crow-Fukase syndrome].
    Arai K.
    Ryoikibetsu Shokogun Shirizu; 2000 Sep; (29 Pt 4):367-9. PubMed ID: 11031971
    [No Abstract] [Full Text] [Related]

  • 11. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor.
    Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D.
    Nat Med; 2001 May; 7(5):569-74. PubMed ID: 11329058
    [Abstract] [Full Text] [Related]

  • 12. A potential autocrine role for vascular endothelial growth factor in prostate cancer.
    Jackson MW, Roberts JS, Heckford SE, Ricciardelli C, Stahl J, Choong C, Horsfall DJ, Tilley WD.
    Cancer Res; 2002 Feb 01; 62(3):854-9. PubMed ID: 11830543
    [Abstract] [Full Text] [Related]

  • 13. [A case of anaphylactoid shock occurring immediately after the initiation of second intravenous administration of high-dose immunoglobulin (IVIg) in a patient with Crow-Fukase syndrome].
    Takahashi T, Ono S, Ogawa K, Tamura M, Mizutani T.
    Rinsho Shinkeigaku; 2003 Jun 01; 43(6):350-5. PubMed ID: 14503355
    [Abstract] [Full Text] [Related]

  • 14. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ.
    Clin Cancer Res; 2000 Mar 01; 6(3):957-65. PubMed ID: 10741721
    [Abstract] [Full Text] [Related]

  • 15. [Pathology of Crow-Fukase syndrome].
    Kanda T.
    Brain Nerve; 2008 Jun 01; 60(6):603-10. PubMed ID: 18567355
    [Abstract] [Full Text] [Related]

  • 16. Vascular endothelial growth factor fails to acutely modulate endothelial permeability during early angiogenesis in the chick chorioallantoic membrane.
    DeFouw LM, DeFouw DO.
    Microvasc Res; 2000 Nov 01; 60(3):212-21. PubMed ID: 11078637
    [Abstract] [Full Text] [Related]

  • 17. [The role of interleukin-6 in Crow-Fukase syndrome].
    Hitoshi S, Sato K, Suzuki K, Sato K, Sakuta M.
    Rinsho Shinkeigaku; 1992 Jun 01; 32(6):577-82. PubMed ID: 1424334
    [Abstract] [Full Text] [Related]

  • 18. Effect of vascular endothelial growth factor on cultured endothelial cell monolayer transport properties.
    Chang YS, Munn LL, Hillsley MV, Dull RO, Yuan J, Lakshminarayanan S, Gardner TW, Jain RK, Tarbell JM.
    Microvasc Res; 2000 Mar 01; 59(2):265-77. PubMed ID: 10684732
    [Abstract] [Full Text] [Related]

  • 19. Induction of SPARC by VEGF in human vascular endothelial cells.
    Kato Y, Lewalle JM, Baba Y, Tsukuda M, Sakai N, Baba M, Kobayashi K, Koshika S, Nagashima Y, Frankenne F, Noël A, Foidart JM, Hata RI.
    Biochem Biophys Res Commun; 2001 Sep 21; 287(2):422-6. PubMed ID: 11554745
    [Abstract] [Full Text] [Related]

  • 20. [A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma].
    Takakura Y, Yamaguchi Y, Miyoshi T.
    Rinsho Shinkeigaku; 2003 Apr 21; 43(4):170-5. PubMed ID: 12884826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.